91̽

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery
Talk

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal and Thomas Moreau discuss how 91̽ are working to solve the problem of restricted access to reliable human cells using next-generation precision reprogramming technology.
Explore ioCells
Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Dr Thomas Moreau

Head of Research

91̽

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal 

SVP Alliance Management

91̽ 

Kam Dhaliwal and Thomas Moreau discuss how 91̽ are working to solve the problem of restricted access to reliable human cells using next-generation precision reprogramming technology.
Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Dr Thomas Moreau

Head of Research

91̽

Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery

Kam Dhaliwal 

SVP Alliance Management

91̽ 

Listen to our talk at ELRIG Drug Discovery Digital to learn how 91̽’s opti-ox  technology can generate cells with high consistency and functionality at scale from human iPSCs, including those carrying disease-specific mutations, providing high-quality human models for enhanced research outcomes and drug discovery efficiency.

 

Explore ioCells

Related pages

91̽ Learn about our range of human iPSC-derived cells for research and drug discovery
Our platform Discover the cell coding platform behind our cells
Contact us Talk to us to learn more about our team and products